Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CARsgen Therapeutics
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
BMS/bluebird and Janssen/Legend have the leading BCMA-targeting CAR-T therapies for multiple myeloma but Poseida, Allogene, CARsgen, Gracell and CBMG are emerging with novel approaches.
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
It's been a big week for cell therapy developers in China with well over $500m raised through an IPO and large new funding rounds for several other ventures.
- Gene Therapy, Cell Therapy